Covis granted FDA hearing in latest twist over controversial premature-birth med Makena

[cafead]

via Nearly two years after an FDA advisory panel determined Covis Pharma’s controversial premature-birth med Makena should be taken off the market after failing a key post-approval study, the agency is giving the company a chance to plead its case.

article source